Tag: Press Releases,financing

  Biodesix, Inc., a molecular diagnostics company that discovers, develops and commercializes blood tests to deliver personalized medicine in oncology, announced today that the company raised $22 million through the sale of series F preferred stock and other securities.  This amount includes capital previously raised through convertible debt and converted into equity in the series…